These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37068580)

  • 41. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural Studies of Matrix Metalloproteinase by X-Ray Diffraction.
    Decaneto E; Lubitz W; Ogata H
    Methods Mol Biol; 2017; 1579():49-60. PubMed ID: 28299732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
    Kim IS; Yang WS; Kim CH
    Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
    Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
    Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
    Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition.
    Jiang B; Zhang Y; Liu J; Tsigkou A; Rapti M; Lee MH
    Oncotarget; 2017 Apr; 8(14):22685-22699. PubMed ID: 28186971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation.
    Zhao H; Bernardo MM; Osenkowski P; Sohail A; Pei D; Nagase H; Kashiwagi M; Soloway PD; DeClerck YA; Fridman R
    J Biol Chem; 2004 Mar; 279(10):8592-601. PubMed ID: 14681236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.
    Nam DH; Rodriguez C; Remacle AG; Strongin AY; Ge X
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):14970-14975. PubMed ID: 27965386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Dynamics Simulations of Matrix Metalloproteinase 13 and the Analysis of the Specificity Loop and the S1'-Site.
    Choi JY; Chung E
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases.
    Park JY; Park JH; Jang W; Hwang IK; Kim IJ; Kim HJ; Cho KH; Lee ST
    J Biochem; 2012 Mar; 151(3):291-8. PubMed ID: 22170214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.
    Nam DH; Fang K; Rodriguez C; Lopez T; Ge X
    Protein Eng Des Sel; 2017 Feb; 30(2):113-118. PubMed ID: 27986919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.
    Remacle AG; Shiryaev SA; Radichev IA; Rozanov DV; Stec B; Strongin AY
    J Biol Chem; 2011 Jun; 286(23):21002-12. PubMed ID: 21518756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure and computation-guided yeast surface display for the evolution of TIMP-based matrix metalloproteinase inhibitors.
    Shoari A; Khalili-Tanha G; Coban MA; Radisky ES
    Front Mol Biosci; 2023; 10():1321956. PubMed ID: 38074088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of Novel Natural Product Inhibitors against Matrix Metalloproteinase 9 Using Quantum Mechanical Fragment Molecular Orbital-Based Virtual Screening Methods.
    Lim H; Hong H; Hwang S; Kim SJ; Seo SY; No KT
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of potent and specific inhibitors targeting the active site of MMP-9 from the engineered SPINK2 library.
    Yano H; Nishimiya D; Kawaguchi Y; Tamura M; Hashimoto R
    PLoS One; 2020; 15(12):e0244656. PubMed ID: 33373399
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.